TLS Detect RUO

Set the standard for TLS detection

An AI tool that detects Tertiary Lymphoid Structures across tumor types from digitized H&E slides
Request a demoCase Study

Clinical context

Gain insights into a tumor's interaction with the immune system

TLS provide crucial insights to better understand the response to immunotherapies*

Prognostic role
A major player in antitumor immune response, the presence of TLS has been associated with improved survival in several tumor types.1
Predictive biomarker
During drug development and clinical trials TLS can serve as a predictive biomarker for response to certain immunotherapies.
Therapeutic target
Presence of TLS potentially indicates an enhanced immune response making it a possible target for improved response to immunotherapy.2
Combination therapies
TLS could guide the development of therapies that target both the tumor cells and the local immune environment.
Trial optimization
TLS can support clinical trial optimization, to help better select trial participants to improve success rates across trial phases.

Benefits of TLS detection

As a novel biomarker, TLS presence helps stratify the overall survival risk of untreated cancer patients and helps identify those who may benefit from efficient immunotherapy treatment.

Owkin’s simple and standardized approach could support the adoption of this biomarker as an independent predictor of response to immune checkpoint inhibitors (ICI).

With a sensitivity of 97%, TLS Detect supports the screening for TLS presence across tumors within a research setting.

TLS Detect RUO

An automated solution providing standardized quick results‍

Testing tumor specimens
Pan-tumor

Suitable for tumor specimens across multiple indications

Digital pathology
Digital pathology

Works with tumor tissue on digitized H&E slides

97% sensitivity
Sensitivity**

Externally validated high sensitivity

Intended users icon
Intended users

Researchers in a non-clinical routine setting

PDF report
PDF report

Delivered as a PDF with intuitive design

Heatmap
Dynamic heatmap

Notes the presence or absence of TLS with score predictions‍

MSIntuit TabletMSIntuit Screen

In a research setting

Determine the status of TLS

Sample

Tissue sample is taken and prepared as H&E slide

Digitization

H&E slide digitized

AI solution

TLS Detect extracts and analyzes features from the digitized slide

TLS Detect

PDF Report with dynamic heat map

Results

Results
‍
TLS

Presence of TLS, with analysis score provided

No TLS

No presence of TLS, with analysis score provided

"As a research tool, TLS Detect has the potential to pre-screen for TLS positive tumor samples, paving the way for optimization of research workflows in multiple tumor indications."
Antonie Italiano MD, PhD
Professor of Medicine & Head of Early Phase Trials Unit, Institut Bergonie, France
TLS Detect RUO was developed with annotated data from Comprehensive Cancer Center and a long-time partner of Owkin, Institut Bergonié.

Citations

  1. Vanhersecke et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer Vol 2 794-802 (Aug 2021)
  2. Srivastava et al. IMpower110: Tertiary lymphoid structures and clinical outcomes in advanced non-small cell lung cancer treated with first-line atezolizumab or chemotherapy. Presented at The Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. (November 2023).
* Research tool only not to be used for diagnostic purposes
**97% sensitivity was achieved through validation on an external dataset (n=157 patients)
Manufacturer: Owkin France. TLS Detect is a deep learning software, intended to assist researchers in the detection of tertiary lymphoid structures based on digital histology slides. TLS Detect is for Research Use Only. Not for use in diagnostic procedures. Information updated on 29th October 2024 - Version W003V2